What this study is
This study is a randomized, non-inferiority clinical trial evaluating a human milk concentration (HMC) device in preterm infants. The trial compares outcomes in infants fed mother's own milk (MOM) concentrated using the HMC device to those receiving standard of care feeding with MOM supplemented with cow's milk-based fortifiers or formula.
The primary objective is to determine whether infants receiving HMC-concentrated MOM achieve growth and mineral status that are non-inferior to standard of care, as measured by growth velocity through 28 days of life or hospital discharge and serum phosphate levels at 14 days of life.
Secondary objectives include assessment of clinical safety through evaluation of feeding tolerance, weight gain, and serum chemistries during the study period. The study will also evaluate the cost and resource utilization associated with feeding strategies by comparing preparation time, supply costs, total feeding costs, and overall neonatal intensive care unit (NICU) cost of care, including length of stay.
What's being tested
- Human Milk Concentration Device
Intervention · DEVICE
A sterile, single-use human milk concentration device used to passively remove water from mother's own milk prior to feeding, increasing nutrient density without the addition of bovine-derived fortifier.
- Standard of Care Fortified Feeding
Intervention · OTHER
Mother's own milk supplemented with cow's milk-based human milk fortifier and/or formula according to institutional standard of care.
Study details
- Official title
- Noninferiority Evaluation of Human Milk Concentrating Device to Optimize Mother's Own Milk
- Sponsor
- Mother's Milk is Best
- Conditions
- Preterm Infant Health · Premature Babies
- Enrolling
- 310 people
- Starts
- 2026-09-01
- Est. completion
- 2028-07-01
- Design
- Double-blind, randomized, parallel groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 32 Weeks – 35 WeeksSex ALLHealthy volunteers Not acceptedYou may qualify if
- Birth at 32 0/7 to 34 5/7 weeks' gestational age, with a birthweight above 1500 grams and receiving MOM
- Enteral feeding must be initiated within 48 hours post-birth and the infant must meet the NICU's clinical guidelines for feed fortification/supplementation.
- Multiples are eligible and will be randomized to the same group since the intervention affects MOM preparation.
You can't join if
- Major congenital anomalies
- Contraindication to receiving MOM
- Feeds not started by 2 days post-birth
- Fortification/supplementation not ordered by 5 days post-birth,
- Inadequate MOM for concentration/fortification within 5 days post-birth
- Expected transfer to another hospital
- Expected hospital discharge within 14 days post-birth
- Enrollment in another intervention study with an intervention that could affect infant growth or mineral status
- Infant with contraindications for use of the HMC device
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openYale University
New Haven, Connecticut, United States
Study team
Sponsor
Mother's Milk is Best
Study ID MMIB-NEOMOM-2000042290
Principal investigator
Sarah Taylor, MD
Yale University
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.